Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis

Epidemiology and Infection

Volumn 133, Issue 4, 2005, Pages 737-748

  Versteegh, Florens G A ^a   Mertens, P L J M ^b   de Melker, H E ^c   Roord, J J ^d   Schellekens, J F P ^c   Teunis, P F M ^c  

^a GROENE HART HOSPITAL   (Netherlands)

^b Public Health Service of the Rotterdam Region   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY DETECTION; ARTICLE; BACTERIAL IMMUNITY; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; INFANT; INFECTION RISK; LONG TERM CARE; MAJOR CLINICAL STUDY; PERTUSSIS; REINFECTION; SERODIAGNOSIS; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; NETHERLANDS; PERTUSSIS TOXIN; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 22544438467     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268805003833     Document Type: Article

References (41)

1. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J 1988; 296: 612-614.
2. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161: 480-486.
3. Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995; 346: 1326-1329.
4. Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infection in adolescents. Am J Dis Child 1993; 147: 575-577.
5. Laing JS, Hay M. Whooping-cough: its prevalence and mortality in Aberdeen. Public Health 1902; 14: 584-598.
6. Luttinger P. The epidemiology of pertussis. Am J Dis Child 1916; 12: 290-315.
7. Long SS, Lischner HL, Deforest A, Clark JL. Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 1990; 9: 700-705.
8. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent Country, Michigan. Public Health Rep 1965; 80: 365-369.
9. Hodder SL, Cherry JD, Mortimer Jr. EA, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis 2000; 31: 7-14.
10. Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis 1995; 21: 639-642.
11. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183: 1353-1359.
12. Versteegh FGA, Schellekens JFP, Nagelkerke AF, Roord JJ. Laboratory-confirmed re-infections with Bordetella pertussis. Acta Paediatr 2002: 91: 95-97.
13. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-1916.
14. Hewlett EL, Halperin SA. Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 46: 1899-1900.
15. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-1906.
16. Zackrisson G, Taranger J, Trollfors B. History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr 1990; 116: 190-194.
17. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003; 21: 3542-3549.
18. Halperin SA, Scheifele D, Barreto L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1999; 18: 772-779.
19. Melker HE de, Versteegh FGA, Conyn-van Spaendonck MAE, et al. Specificity and sensitivity of high levels of Immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38: 800-806.
20. Cherry JD, Olin P. The science and fiction of pertussis vaccines. Pediatr 1999; 104: 1381-1384.
21. Zee A van der, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J Infect Dis 1996; 174: 89-96.
22. Müller F-MC, Hoppe JE, Wirsing von König CH. Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 1997; 35: 2435-2443.
23. Mertens PLJM, Stals FS, Schellekens JFP, Houben AW, Huisman J. An epidemic of pertussis among elderly people in a religious institution in the Netherlands. Eur J Clin Microbiol Infect Dis 1999; 18: 242-247.
24. Teunis PFM, Heijden OG van der, Melker HE de, Schellekens JFP, Versteegh FGA, Kretzschmar M. Kinetics of IgG-antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 2002; 129: 479-489.
25. Schellekens JFP, Boshuizen HC, Verbakel JMM, et al. Serodiagnosis of pertussis with commercial ELISAs. ICAAC, Chicago USA, 22-25 September 2001, Abstract book, p. 163, Abstract no. D-1403.
26. Nagel J, de Graaf S, Schijf-Evers D. Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Dev Biol Stand 1985; 61: 325-330.
27. Lynn F, Reed GF, Meade BD. A comparison of enzyme immuno-assays used to measure serum antibodies to components of Bordetella pertussis. Dev Biol Stand 1997; 89: 197-204.
28. Lynn F, Reed GF, Meade BD. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 1996; 3: 689-700.
29. Giammanco A, Chiarini A, Maple PAC, et al. European sero-epidemiology network: standardisation of the assay results for pertusis. Vaccine 2003; 22: 112-120.
30. Edelstein-Keshet L. Mathematical models in biology. Birkhäuser Mathematics Series. New York: McGraw-Hill, 1988.
31. Gilks WR, Richardson S, Spiegelhalter DJ (eds). Markov chain Monte Carlo in practice. London: Chapman and Hall, 1996.
32. Heininger U, Cherry JD, Stehr K. Serological response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004; 38: 591-594.
33. Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995; 27: 273-277.
34. Tomoda T, Ogura H, Kurashige T. The longevity of the immune response to filamentous hemaglutinin and pertussis toxin in patients with pertussis in a semiclosed community. J Infect Dis 1992; 166: 908-910.
35. Tomoda T, Ogura H, Kurashige T. Immune responses to Bordetella pertussis infection and vaccination. J Infect Dis 1991; 163: 559-563.
36. Poovorawan Y, Theamboonlers A, Sanpavat S, Chumdermpadetsuk S, Safary A, Vandepapeliere P. Long-term antibody persistence after booster vaccination with combined tetravalent diphtheria tetanus, whole-cell Bordetella pertussis and hepatitis B vaccine in healthy infants. Ann Tropic Paediatr 1997; 17: 301-308.
37. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998; 132: 983-988.
38. Tran Minh NN, He Q, Edelman K, et al. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults. Vaccine 2000; 18: 1971-1974.
39. Taranger J, Trollfors B, Lagergård T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181: 1010-1013.
40. Granström M, Granström G, Gillenius P, Askelöf P. Neutralizing antibodies to pertussis toxin in whooping cough. J Infect Dis 1985; 151: 646-649.
41. Blennow M, Granström M. Long term serologic follow-up after pertussis immunization. Pediatr Infect Dis J 1990; 9: 21-26.